Driven by increased outsourcing from cost-pressured, limited pipeline biotech and pharmaceutical companies, the market for pharmaceutical contract manufacturing is projected to exceed $31 billion by 2012.
San Jose, Calif. (PRWEB) October 22, 2008 -- Global pharma industry faces numerous challenges in the form of increasing competition in generic markets, rising cost of new product development, declining research and development (R&D) productivity, shrinking average patent life, and mounting governmental pressure to reduce drug prices. Given the backdrop of such a competitive landscape, the decisive factors for growth and sustainability are faster new drug development and cost containment with Pharmaceutical Contract Manufacturing (PCM) emerging as a strategic option offering several advantages.
Firstly, outsourcing provides pharma companies the opportunity to avail flexibility, quicker time to market, and lower scale-up costs. Thus, companies will be able to meet growing demand for new drugs and focus on their core competencies. Secondly, outsourcing enables companies to reduce excess capacity in their manufacturing networks and restructure supply chains. Finally, value-added outsourcing services meet the increased demand for specialized manufacturing capabilities in key technical niches (such as lyophilization) and increased demand for back-up sources of supply.
Global market for pharmaceutical contract manufacturing (PCM) is estimated at US$20.4 billion for 2008, as stated by Global Industry Analysts, Inc. United States is the single largest market for PCM with revenues projected to be US$12.8 billion in 2012. In terms of revenues, although North America and Europe are the largest markets, Asia with its immense manufacturing capacity is projected to exhibit robust growth. Exhibiting a CAGR of nearly 16%, Asia-Pacific is expected to emerge as the fastest growing region in the global PCM market. Injectables (Injections, Vials & Intravenous Solutions) represent the fastest growing product segment, and are forecast to record revenues of US$10.6 billion by 2015. Solid Dosage Forms (Tablets & Capsules), the largest segment, is vibrant with a projected market value of US$12.3 billion for 2010.
European and North American pharmaceutical contract manufacturing sector is three tiered. Tier 1 companies offer end-to-end services ranging from clinical trials to commercial manufacturing, logistics, packaging, and marketing assistance. Tier 2 companies provide services ranging from early stage project development to commercial level manufacturing. Tier 3 companies are conventional manufacturing companies, which address the needs of the generic drugs industry. However, contract manufacturing in Europe is dominated by generic drug variants, while in North America branded versions are preferred. In Asia, numerous local players operate in the market. Key global market participants include Althea Technologies, Catalent Pharma Solutions, Dishman Pharmaceuticals and Chemicals Ltd, DSM Pharmaceuticals, HAUPT Pharma AG, Jubilant Organosys, Kemwell Pvt. Ltd., Nipro Corp, NextPharma, Patheon Inc., Penn Pharmaceutical Services Ltd.
"Pharmaceutical Contract Manufacturing: A Global Strategic Business Report" published by Global Industry Analysts, Inc., analyzes the global market with hard-to-find data and analytics for key regional markets such as the United States and Europe, along with rapidly growing markets such as Asia. The report provides a review of market trends and issues, drivers, players, recent developments, mergers, acquisitions, alliances and other strategic industry activities. Analytical estimates and projections are presented in terms of annual revenues in US$ over the years 2000 through 2010. Long-term projections are presented for the years 2011 through 2015.
For more details about this research report, please visit http://www.strategyr.com/Pharmaceutical_Contract_Manufacturing_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Email press @ StrategyR.com
Web Site http://www.strategyr.com
Read the full story at http://www.prweb.com/releases/contract_manufacturing/pharmaceuticals/prweb1503304.htm
Copyright©2008 Vocus, Inc.
All rights reserved